Key result
BPC 157 counteracts multiorgan failure, thrombosis, and severe ECG disturbances in post-embolization syndrome.
Why the study?
Post-embolization syndrome after inferior caval vein embolization causes severe multiorgan and vessel failure, and effective therapies to resolve this syndrome are needed.
Does pentadecapeptide BPC 157 improve recovery from sodium laurate-induced post-embolization syndrome in rats?
Does pentadecapeptide BPC 157 improve recovery from sodium laurate-induced post-embolization syndrome in rats?
BPC 157 therapy rapidly reverses sodium laurate-induced post-embolization syndrome and multiorgan failure in rats by activating collateral venous pathways.
Should not yet inform clinical embolization management; leaves open BPC 157 translation from this rat model.
After inferior caval vein embolization therapy, post-embolization syndrome (sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein, assessment at 15, 30, 60 min, prime lung lesions, thromboemboli occluding lung vessels), as a severe occlusion/occlusion-like syndrome, might be resolved as a whole by stable gastric pentadecapeptide BPC 157 therapy. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or intragastrically). As before, confronted with the occlusion of major vessel(s) or similar noxious procedures, such as rapidly acting Virchow triad circumstances, the particular effect of the therapy (i.e., collateral pathways activation, "bypassing vascular key", i.e., direct blood flow delivery via activation of azygos vein) assisted in the recovery of the vessel/s and counteracted multiorgan failure due to occlusion/occlusion-like syndrome as a whole in the laurate-injected rats. Along with prime lung lesions and thromboemboli occluding lung vessels, post-embolization syndrome rapidly occurred peripherally and centrally as a shared multiorgan and vessel failure, brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, venous hypertension (intracranial (superior sagittal sinus), portal, and caval), aortal hypotension, progressing thrombosis in veins and arteries and stasis, congested and/or failed major veins, and severe ECG disturbances. Whatever the cause, these were all counteracted, eliminated, or attenuated by the application of BPC 157 therapy. As recovery with BPC 157 therapy commonly and rapidly occurred, reversing the collapsed azygos vein to the rescuing collateral pathway might initiate rapid direct blood delivery and start blood flow reorganization. In conclusion, we suggest BPC 157 therapy to resolve further vascular and embolization injuries.
No takes yet. Share an insight, caveat, or question.
Smoday et al. (2023) studied Inferior caval vein embolization / post-embolization syndrome. Pentadecapeptide BPC 157 was evaluated on Recovery of post-embolization syndrome (multiorgan failure, lung lesions, thromboemboli, venous hypertension, ECG disturbances). Pentadecapeptide BPC 157 therapy counteracted multiorgan failure, thrombosis, and severe ECG disturbances in rats with sodium laurate-induced post-embolization syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: